JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation
Trial ID or NCT#
This is a Phase 1a/b study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in subjects with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) undergoing allogenic blood stem cell transplantation.
A Phase 1a/b Study to Evaluate the Safety & Tolerability of JSP191 in Combination With a Regimen of Low Dose Radiation & Fludarabine in Subjects With MDS or AML Undergoing Hematopoietic Cell Transplantation (HCT)
- - AML/MDS as defined by specific criteria, including but not limited to the following subtypes: 1. AML in CR 2. MDS < 5% BM blasts 3. MDS 5 - 10% BM blasts 4. AML not in CR or MDS > 10% BM blasts - Patients with human leukocyte antigen (HLA) matched related or unrelated donors - Adequate end organ function as defined in study protocol Key
- - Patients with any acute or uncontrolled infections - Patients receiving any other investigational agents - Patients with active non-hematologic malignancy - Prior allogeneic hematologic cell transplantation
Contact us to find out if this trial is right for you.